RECRUITING

Anti-Inflammatory Milk Matrix

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Obesity is pro-inflammatory, impairs metabolism, and physically limiting. Specifically, muscle in obese persons does not synthesize proteins normally. This further increases metabolic and physical dysfunction. As such, obesity programs should not only focus on weight loss, but muscle metabolic health. Dairy nutrients have anti-inflammatory and anabolic properties, but mostly evaluated in isolation and/or pre-clinical designs. Also, it is unknown if the circulating benefits extend to the muscle. We hypothesize that dairy full-fat milk will improve these obesity characteristics.

Official Title

Dairy Food Consumption and Its Effects on Inflammation and the Postprandial Regulation of Muscle Protein Synthesis

Quick Facts

Study Start:2020-02-14
Study Completion:2024-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04216004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 59 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Obese (BMI, body mass index ≥30, \<40 kg•m-2)
  2. * Age 40-59
  3. * Pre-menopausal
  4. * Sedentary/insufficiently active for prior 6 months (mo)
  5. * Weight stable for prior 6 mo
  1. * Tobacco, nicotine (patch/gum) use (previous 6 mo)
  2. * Alcohol consumption \>10 drinks per week
  3. * Metabolic disorders (e.g., Metabolic Syndrome, Diabetes, thyroid diseases)
  4. * Cardiovascular disease, arrhythmias
  5. * Hypogonadism
  6. * Asthma
  7. * History of uncontrolled hypertension
  8. * Orthopedic injury/surgery (within 1 yr)
  9. * Hepatorenal, musculoskeletal, autoimmune, or neurological disease
  10. * History of neuromuscular problems
  11. * Previous participation in amino acid tracer studies
  12. * Predisposition to hypertrophic scarring or keloid formation
  13. * Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
  14. * Consumption of thyroid, androgenic, or other medications known to affect endocrine function
  15. * Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication)
  16. * Pregnancy
  17. * Allergy to dairy product or lactose intolerance
  18. * Fasting plasma glucose (FPG) ≥ 126 mg/dL
  19. * Oral glucose tolerance test (OGTT) ≥ 200 mg/dL

Contacts and Locations

Study Contact

Nicholas A Burd, Ph.D.
CONTACT
217-244-0970
naburd@illinois.edu

Study Locations (Sites)

Freer Hall
Urbana, Illinois, 61801
United States

Collaborators and Investigators

Sponsor: University of Illinois at Urbana-Champaign

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-02-14
Study Completion Date2024-03

Study Record Updates

Study Start Date2020-02-14
Study Completion Date2024-03

Terms related to this study

Additional Relevant MeSH Terms

  • Obesity
  • Skeletal Muscle
  • Inflammation